Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Smolen, 2016, Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force, Ann Rheum Dis, 75, 3, 10.1136/annrheumdis-2015-207524 Parati, 2014, European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring, J Hypertens, 32, 1359, 10.1097/HJH.0000000000000221 Blonde, 2010, Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus, Am J Med, 123, S12, 10.1016/j.amjmed.2009.12.005 2017, Standards of medical care in diabetes, Diabetes Care, 40, S1 Bouguen, 2015, Treat to target: a proposed new paradigm for the management of Crohn's disease, Clin Gastroenterol Hepatol, 13, 1042, 10.1016/j.cgh.2013.09.006 Peyrin-Biroulet, 2015, Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target, Am J Gastroenterol, 110, 1324, 10.1038/ajg.2015.233 Turner, 2021, Gastroenterology, 160, 1570, 10.1053/j.gastro.2020.12.031 Costa, 2005, Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease, Gut, 54, 364, 10.1136/gut.2004.043406 Solem, 2005, Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease, Inflamm Bowel Dis, 11, 707, 10.1097/01.MIB.0000173271.18319.53 Vermeire, 2004, C-reactive protein as a marker for inflammatory bowel disease, Inflamm Bowel Dis, 10, 661, 10.1097/00054725-200409000-00026 Colombel, 2017, Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial, Lancet, 390, 2779, 10.1016/S0140-6736(17)32641-7 Daperno, 2004, Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD, Gastrointest Endosc, 60, 505, 10.1016/S0016-5107(04)01878-4 Rutgeerts, 2018, Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn's disease, Gastroenterology, 155, 1045, 10.1053/j.gastro.2018.06.035 Sandborn, 2020, Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2/3 studies, Inflamm Bowel Dis, 27, 994, 10.1093/ibd/izaa236 Feagan, 2016, Ustekinumab as induction and maintenance therapy for Crohn's disease, N Engl J Med, 375, 1946, 10.1056/NEJMoa1602773 D'Haens, 2021, Pharmacokinetics, immunogenicity, and exposure–response relationships of ustekinumab treatment in patients with Crohn's disease: results from the week 48 treat to target vs standard of care analysis of the Stardust study, United European Gastroenterol J, 9, 542 Khanna, 2015, Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial, Lancet, 386, 1825, 10.1016/S0140-6736(15)00068-9 Adler, 2014, Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany, BMC Gastroenterology, 14, 183, 10.1186/1471-230X-14-183